This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) To 2017: Global Analysis

8.3 Molecular Diagnostics and Personalized Medicine: Value-Assessed Opportunities for Multiple Stakeholders Values, Needs & Expectations

8.4 Regulatory Authorities

8.5 Molecular Diagnostics as Companion Diagnostics: Value-Driven Adoption8.5.1 Behavioral Impact8.5.2 Economic Impact (Value-Based vs. Cost-Plus Pricing)

9. Molecular Diagnostics Clinical Trial Statement9.1 Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples9.2 Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase (ALK) Translocation9.3 A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus9.4 Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler9.5 A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test9.6 Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma9.7 Biopsies of Cancer Patients for Tumor Molecular Characterization9.8 Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia9.9 Collection of Tissue Samples for Cancer Research9.10 Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma9.11 Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia9.12 Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy9.13 Congenital Muscle Disease Study of Patient and Family Reported Medical Information9.14 Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates9.15 Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase9.16 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib9.17 Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile9.18 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients9.19 Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients9.20 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

10. Molecular Diagnostics Market – Drivers10.1 Various Developments in the Molecular Diagnostics Landscape10.2 Increasing Investment in Genomics & Proteomics Research10.3 Technological Advances in Molecular Diagnostics10.4 Increasing Acceptance of the Personalized Medicine10.5 Growing Molecular Diagnostics for Food Safety

11. Molecular Diagnostics Market – Challenges11.1 Regulatory Issues11.2 Various Factors Slowing Growth of Molecular Diagnostics11.3 Reimbursement Capabilities11.4 Quality Checkpoints, Awareness & Acceptance

List of Figures:

Figure 2 1: Global – Molecular Diagnostics Market (Million US$), 2010 – 2012Figure 2 2: Global – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017Figure 3 1: Global Molecular Diagnostics – Application Wise Market Share (Percent), 2010 – 2012Figure 3 2: Global Molecular Diagnostics – Forecast for Application Wise Market Share (Percent), 2013 – 2017Figure 3 3: Global Molecular Diagnostics – Technology Wise Market Share (Percent), 2010 – 2012Figure 3 4: Global Molecular Diagnostics – Forecast for Technology Wise Market Share (Percent), 2013 – 2017Figure 3 5: Global Molecular Diagnostics – Region Wise Market Share (Percent), 2010 – 2012Figure 3 6: Global Molecular Diagnostics – Forecast for Region Wise Market Share (Percent), 2013 – 2017

4 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs